Compare Pfizer Inc (PFE) vs Verizon Communications Inc (VZ) Price & Performance

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.

Verizon (VZ) trades at $45.77, down 0.46% on the day, with a bearish technical outlook but strong fundamentals. The stock shows consistent earnings beats, with Q3 2026 results due October 26, 2026. Valuation metrics are attractive, including a P/E of 11.92 and EV/EBITDA of 7.85. Cash flow improved significantly in 2025, with net cash flow of $14.9 billion, supporting a stable dividend. Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand coverage and the election of Charles Phillips to the board.

Outlook: Verizon offers value with solid dividends and cash flow, but faces competitive pressures and debt concerns. Risks include industry competition and capital expenditure demands. Analyst consensus is mixed, with a $48.58 price target suggesting modest upside. The stock remains a defensive play in telecom with income appeal, though growth is tempered by market saturation.